Is NSRX or NVO more undervalued in 2026?

CirclFi compares Nasus Pharma Ltd. (NSRX) and Novo Nordisk A/S (NVO) using 13 institutional-grade valuation models. NSRX has a Quality of Company score of 1.9/10 while NVO scores 10.0/10.

Which is a better buy — NSRX or NVO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NSRX and NVO valuations compare?

NSRX at $3.20 and NVO at $45.51 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NSRX vs NVO Valuation Comparison 2026 — Intrinsic Value Analysis

NSRX

Drug Manufacturers - General

Nasus Pharma Ltd.

Quality

1.9

out of 10

Value Trap

—

Price

$3.20

Last close

Models

7/13

Active

NVO

Drug Manufacturers - General

Novo Nordisk A/S

Quality

10.0

out of 10

Value Trap

SAFE

Price

$45.51

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	NSRX Fair Value	NSRX Upside	NVO Fair Value	NVO Upside
Bayesian DCF	Intrinsic	$0.85	-73.5%	$31.50	-30.8%
Earnings Power Value	Intrinsic	—	—	$44.05	-3.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$2.27	-24.8%	$54.46	+19.7%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NSRX vs NVO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NSRX vs NVO — Which Stock Is More Undervalued?

NVO scores higher with a 10.0/10 quality rating vs NSRX's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Nasus Pharma Ltd. (NSRX) and Novo Nordisk A/S (NVO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NSRX currently trades at $3.20 with a QOC of 1.9/10, while NVO trades at $45.51 with a QOC of 10.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).